Approaches and Challenges in SARS-CoV-2 Vaccine Development

Cell Host Microbe. 2020 Sep 9;28(3):364-370. doi: 10.1016/j.chom.2020.08.002. Epub 2020 Aug 10.

Abstract

The explosive spread of SARS-CoV-2 suggests that a vaccine will be required to end this global pandemic. Progress in SARS-CoV-2 vaccine development to date has been faster than for any other pathogen in history. Multiple SARS-CoV-2 vaccine candidates have been evaluated in preclinical models and are currently in clinical trials. In this Perspective, we discuss three topics that are critical for SARS-CoV-2 vaccine development: antigen selection and engineering, preclinical challenge studies in non-human primate models, and immune correlates of protection.

Keywords: COVID-19; SARS-CoV-2; vaccine.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antigens, Viral / chemistry
  • Antigens, Viral / genetics
  • Betacoronavirus* / genetics
  • Betacoronavirus* / immunology
  • COVID-19
  • COVID-19 Vaccines
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / immunology*
  • Coronavirus Infections / prevention & control*
  • Host Microbial Interactions / immunology
  • Humans
  • Immunity, Cellular
  • Immunity, Humoral
  • Immunity, Innate
  • Models, Animal
  • Pandemics / prevention & control*
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / immunology*
  • Pneumonia, Viral / prevention & control*
  • Primates
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus / chemistry
  • Spike Glycoprotein, Coronavirus / genetics
  • Spike Glycoprotein, Coronavirus / immunology
  • Viral Vaccines / administration & dosage
  • Viral Vaccines / immunology
  • Viral Vaccines / isolation & purification*

Substances

  • Antigens, Viral
  • COVID-19 Vaccines
  • Spike Glycoprotein, Coronavirus
  • Viral Vaccines
  • spike protein, SARS-CoV-2